The Association of the British Pharmaceutical Industry (ABPI) reposted this
Co-Founder and Managing Partner at CF. Healthcare consulting and data science. Experts in healthcare. Supporting health system, life sciences, health investors to improve outcomes via uptake of innovation and use of data
I’m pleased to share CF's latest report with The Association of the British Pharmaceutical Industry (ABPI). This world-first research, set out to systematically measure how NHS-industry partnerships support improved patient outcomes using data from across the NHS: - We found that hospitals that undertake partnerships are up to 2.5 times more likely to prescribe clinically and cost-effective medicines more closely in line with NICE - National Institute for Health and Care Excellence recommendations compared to hospitals that do not. - Such prescribing patterns were, in turn, associated with better outcomes for patients in the areas of care studied. There were also early indications that partnerships in PCNs were associated with improved disease management, such as blood sugar and blood pressure control. - The first-of-its-kind research looked specifically at partnerships tackling cardiovascular disease, cholesterol control and diabetes, as major priority areas of care for the NHS. We're witnessing growing levels of interest in partnerships between industry and the NHS to drive innovation. Launching a new drug is only part of the equation - true patient outcomes are achieved when we also address system-wide barriers such as patient identification, adherence, and best practice sharing. By leveraging data, technology, and collaboration, partnerships can create new opportunities to improve and sustain healthcare delivery. It is exciting that we have generated evidence to highlight their potential. I would also observe 3 things 💡 1. The focus of all these partnerships has been on the adoption of innovation in context of being judged safe and clinically effective by MHRA, cost effective by NICE, and affordable by the NHSE; and hence the aim ought to be ensuring patient access to these proven interventions 2. The ABPI has clear guidelines for the establishment and operation of partnerships within the framework of the code of conduct which is overseen independently by the PMPCA 3. Despite the huge potential for partnership, there is gulf of both understanding and trust between industry and the NHS which may be one of the biggest barriers to impact This report is just the start of considering how can partnership improve outcomes. I’d be interested to understand views of: - What’s your experience of NHS-industry partnership work? - What are the key factors that drive impact - and sustain it? - What does the NHS value most in partnership with industry and vice versa? - What are the key barriers in enabling partnerships and how can these be addressed? I would love to hear your thoughts, and please get in touch if you’d like to find out more. ⤵ https://lnkd.in/eEdDcZ-a Department of Health and Social Care Medicines and Healthcare products Regulatory Agency NHS England Russell Abberley Richard Torbett MBE Samantha Roberts Fiona Bride Verena Stocker Ming Tang Roland Sinker